Detecting and targeting tumor relapse by its resistance to innate effectors at early recurrence

Area of Science:

• Oncology
• Immunology
• Cancer Research

Background:

• Tumor recurrence is a significant clinical problem.
• Recurrent tumors often exhibit distinct phenotypes compared to primary tumors.
• Minimal residual disease (MRD) can progress to actively growing recurrence, evading immune responses.

Purpose of the Study:

• To investigate the phenotypic changes in recurrent tumors.
• To identify mechanisms by which recurrent tumors evade innate immunity.
• To develop strategies for predicting and treating tumor recurrence.

Main Methods:

• Phenotypic analysis of primary and recurrent tumors in a mouse model.
• Screening for innate immune responses associated with recurrence.
• Investigating the effect of premature recurrence induction on therapy sensitivity.
• Evaluating combination therapies targeting innate immune insensitivity.

Main Results:

• Recurrent tumors acquire a phenotype that evades host innate immune responses.
• Screening for innate immune response accurately predicted tumor recurrence in mice.
• Prematurely induced recurrence sensitized minimal residual disease to primary therapy.
• Combination of screening and targeted second-line treatments achieved a 100% cure rate in mice that would have relapsed.

Conclusions:

• Emergent recurrent tumors develop immune-evasive phenotypes.
• Early detection of immune escape mechanisms is crucial for predicting recurrence.
• Active intervention to resensitize minimal residual disease before phenotype evolution offers a new treatment paradigm.
• Targeted therapies combined with screening show promise for curing tumor recurrence.